;PMID: 9680114
;source_file_537.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..30] = [t:0..30]
;1)sentence:[e:35..174] = [t:35..174]
;2)section:[e:178..298] = [t:178..298]
;3)section:[e:302..370] = [t:302..370]
;4)sentence:[e:374..490] = [t:374..490]
;5)sentence:[e:491..627] = [t:491..627]
;6)sentence:[e:628..819] = [t:628..819]
;7)sentence:[e:820..991] = [t:820..991]
;8)sentence:[e:993..1145] = [t:993..1145]
;9)sentence:[e:1147..1241] = [t:1147..1241]
;10)section:[e:1245..1289] = [t:1245..1289]

;section 0 Span:0..30
;Leuk Res  1998 Jul;22(7):631-7
(SEC
  (FRAG (DT:[0..4] Leuk) (NNP:[5..8] Res) (CD:[10..14] 1998) (CD:[15..20] Jul;2)
        (CD:[20..21] 2) (NN:[21..22] -LRB-) (NN:[22..23] 7) (NN:[23..24] -RRB-)
        (,:[24..25] :) (CD:[25..27] 63) (CD:[27..30] 1-7)))

;sentence 1 Span:35..174
;Significance of chromosomal alterations and mutations of the N-RAS and TP53 
;genes in relation to leukemogenesis of acute myeloid leukemia.
;[51..74]:variation-event:"chromosomal alterations"
;[79..88]:variation-event:"mutations"
;[96..101]:gene-rna:"N-RAS"
;[106..110]:gene-rna:"TP53"
;[151..173]:malignancy:"acute myeloid leukemia"
(SENT
  (NP-HLN
    (NP (NN:[35..47] Significance))
    (PP (IN:[48..50] of)
      (NP
        (NP
          (NP
            (ADJP-2 (JJ:[51..62] chromosomal))
            (NNS:[63..74] alterations))
          (CC:[75..78] and)
          (NP
            (ADJP-2 (-NONE-:[78..78] *P*))
            (NNS:[79..88] mutations)))
        (PP (IN:[89..91] of)
          (NP (DT:[92..95] the)
            (NML
              (NML (NN:[96..101] N-RAS)
                (NML-1 (-NONE-:[101..101] *P*)))
              (CC:[102..105] and)
              (NML (NN:[106..110] TP53)
                (NP-1 (NNS:[112..117] genes))))))))
    (PP (IN:[118..120] in)
      (NP
        (NP (NN:[121..129] relation))
        (PP (TO:[130..132] to)
          (NP
            (NP (NN:[133..147] leukemogenesis))
            (PP (IN:[148..150] of)
              (NP (JJ:[151..156] acute) (JJ:[157..164] myeloid)
                  (NN:[165..173] leukemia)))))))
    (.:[173..174] .)))

;section 2 Span:178..298
;Misawa S, Horiike S, Kaneko H, Sasai Y, Ueda Y, Nakao M, Yokota S, Taniwaki
;M,  Fujii H, Nakagawa H, Tsuda S, Kashima K.
(SEC
  (FRAG (NNP:[178..184] Misawa) (NNP:[185..186] S) (,:[186..187] ,)
        (NNP:[188..195] Horiike) (NNP:[196..197] S) (,:[197..198] ,)
        (NNP:[199..205] Kaneko) (NNP:[206..208] H,) (NNP:[209..214] Sasai)
        (NNP:[215..216] Y) (,:[216..217] ,) (NNP:[218..222] Ueda)
        (NNP:[223..224] Y) (,:[224..225] ,) (NNP:[226..231] Nakao)
        (NNP:[232..234] M,) (NNP:[235..241] Yokota) (NNP:[242..243] S)
        (,:[243..244] ,) (NNP:[245..253] Taniwaki) (NNP:[254..256] M,)
        (NNP:[258..263] Fujii) (NNP:[264..266] H,) (NNP:[267..275] Nakagawa)
        (NNP:[276..278] H,) (NNP:[279..284] Tsuda) (NNP:[285..286] S)
        (,:[286..287] ,) (NNP:[288..295] Kashima) (NNP:[296..298] K.)))

;section 3 Span:302..370
;Division of Hematology, Kyoto Prefectural Yosanoumi Hospital, Japan.
(SEC
  (FRAG (NNP:[302..310] Division) (IN:[311..313] of) (NNP:[314..324] Hematology)
        (,:[324..325] ,) (NNP:[326..331] Kyoto) (NNP:[332..343] Prefectural)
        (NNP:[344..353] Yosanoumi) (NNP:[354..362] Hospital) (,:[362..363] ,)
        (NNP:[364..369] Japan) (.:[369..370] .)))

;sentence 4 Span:374..490
;We examined chromosomes and mutations of the N-RAS and TP53 genes in 73
;patients  with acute myeloid leukemia (AML).
;[402..411]:variation-event:"mutations"
;[419..424]:gene-rna:"N-RAS"
;[429..433]:gene-rna:"TP53"
;[461..483]:malignancy:"acute myeloid leukemia"
;[485..488]:malignancy:"AML"
(SENT
  (S
    (NP-SBJ (PRP:[374..376] We))
    (VP (VBD:[377..385] examined)
      (NP
        (NP (NNS:[386..397] chromosomes) (CC:[398..401] and)
            (NNS:[402..411] mutations))
        (PP (IN:[412..414] of)
          (NP (DT:[415..418] the)
            (NML
              (NML (NN:[419..424] N-RAS)
                (NML-1 (-NONE-:[424..424] *P*)))
              (CC:[425..428] and)
              (NML (NN:[429..433] TP53)
                (NML-1 (NNS:[434..439] genes)))))))
      (PP-LOC (IN:[440..442] in)
        (NP
          (NP (CD:[443..445] 73) (NNS:[446..454] patients))
          (PP (IN:[456..460] with)
            (NP
              (NP (JJ:[461..466] acute) (JJ:[467..474] myeloid)
                  (NN:[475..483] leukemia))
              (NP (-LRB-:[484..485] -LRB-) (NN:[485..488] AML)
                  (-RRB-:[488..489] -RRB-)))))))
    (.:[489..490] .)))

;sentence 5 Span:491..627
;Twenty-six patients showed a reciprocal  chromosomal translocation or an
;inversion, and 34 patients showed only  unbalanced aberrations.
;[520..557]:variation-type:"reciprocal  chromosomal translocation"
;[564..573]:variation-type:"inversion"
(SENT
  (S
    (S
      (NP-SBJ (CD:[491..501] Twenty-six) (NNS:[502..510] patients))
      (VP (VBD:[511..517] showed)
        (NP
          (NP (DT:[518..519] a)
             (JJ:[520..530] reciprocal) (JJ:[532..543] chromosomal)
             (NN:[544..557] translocation))
          (CC:[558..560] or)
          (NP (DT:[561..563] an) (NN:[564..573] inversion)))))
    (,:[573..574] ,) (CC:[575..578] and)
    (S
      (NP-SBJ (CD:[579..581] 34) (NNS:[582..590] patients))
      (VP (VBD:[591..597] showed)
        (ADVP (RB:[598..602] only))
        (NP (JJ:[604..614] unbalanced) (NNS:[615..626] aberrations))))
    (.:[626..627] .)))

;sentence 6 Span:628..819
;Balanced aberrations were predominantly detected in the  AML patients who did
;not have myelodysplasia, preceding myelodysplastic  syndrome, and a history
;of chemotherapy or radiation therapy.
;[628..648]:variation-event:"Balanced aberrations"
;[685..688]:malignancy:"AML"
;[715..729]:malignancy:"myelodysplasia"
;[741..766]:malignancy:"myelodysplastic  syndrome"
(SENT
  (S
    (NP-SBJ-2 (JJ:[628..636] Balanced) (NNS:[637..648] aberrations))
    (VP (VBD:[649..653] were)
      (ADVP (RB:[654..667] predominantly))
      (VP (VBN:[668..676] detected)
        (NP-2 (-NONE-:[676..676] *))
        (PP-LOC (IN:[677..679] in)
          (NP
            (NP (DT:[680..683] the) (NN:[685..688] AML)
                (NNS:[689..697] patients))
            (SBAR
              (WHNP-1 (WP:[698..701] who))
              (S
                (NP-SBJ-1 (-NONE-:[701..701] *T*))
                (VP (VBD:[702..705] did) (RB:[706..709] not)
                  (VP (VB:[710..714] have)
                    (NP
                      (NP (NN:[715..729] myelodysplasia))
                      (,:[729..730] ,)
                      (NP (VBG:[731..740] preceding)
                         (JJ:[741..756] myelodysplastic)
                         (NN:[758..766] syndrome))
                      (,:[766..767] ,) (CC:[768..771] and)
                      (NP
                        (NP (DT:[772..773] a) (NN:[774..781] history))
                        (PP (IN:[782..784] of)
                          (NP
                            (NP (NN:[785..797] chemotherapy))
                            (CC:[798..800] or)
                            (NP (NN:[801..810] radiation)
                                (NN:[811..818] therapy))))))))))))))
    (.:[818..819] .)))

;sentence 7 Span:820..991
;In contrast,  unbalanced aberrations were more frequently seen in the
;patients with AML with  trilineage myelodysplasia, AML transformed from MDS,
;and therapy-related AML.
;[904..907]:malignancy:"AML"
;[914..939]:malignancy:"trilineage myelodysplasia"
;[941..944]:malignancy:"AML"
;[962..965]:malignancy:"MDS"
;[987..990]:malignancy:"AML"
(SENT
  (S
    (PP (IN:[820..822] In)
      (NP (NN:[823..831] contrast)))
    (,:[831..832] ,)
    (NP-SBJ-1 (JJ:[834..844] unbalanced) (NNS:[845..856] aberrations))
    (VP (VBD:[857..861] were)
      (ADVP (RBR:[862..866] more) (RB:[867..877] frequently))
      (VP (VBN:[878..882] seen)
        (NP-1 (-NONE-:[882..882] *))
        (PP-LOC (IN:[883..885] in)
          (NP
            (NP (DT:[886..889] the) (NNS:[890..898] patients))
            (PP (IN:[899..903] with)
              (NP
                (NP
                  (NP (NN:[904..907] AML))
                  (PP (IN:[908..912] with)
                    (NP (NN:[914..924] trilineage)
                        (NN:[925..939] myelodysplasia))))
                (,:[939..940] ,)
                (NP
                  (NP (NN:[941..944] AML))
                  (VP (VBN:[945..956] transformed)
                    (NP (-NONE-:[956..956] *))
                    (PP (IN:[957..961] from)
                      (NP (NN:[962..965] MDS)))))
                (,:[965..966] ,) (CC:[967..970] and)
                (NP
                  (ADJP (NN:[971..978] therapy) (HYPH:[978..979] -)
                        (VBN:[979..986] related))
                  (NN:[987..990] AML))))))))
    (.:[990..991] .)))

;sentence 8 Span:993..1145
;Twenty-two mutations of the N-RAS and TP53 genes were detected, and these 
;mutations were frequently associated with unbalanced chromosomal
;aberrations.
;[1021..1026]:gene-rna:"N-RAS"
;[1031..1035]:gene-rna:"TP53"
;[1061..1077]:variation-event:"these  mutations"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (CD:[993..1003] Twenty-two) (NNS:[1004..1013] mutations))
        (PP (IN:[1014..1016] of)
          (NP (DT:[1017..1020] the)
            (NML
              (NML (NN:[1021..1026] N-RAS)
                (NML-1 (-NONE-:[1026..1026] *P*)))
              (CC:[1027..1030] and)
              (NML (NN:[1031..1035] TP53)
                (NML-1 (NNS:[1036..1041] genes)))))))
      (VP (VBD:[1042..1046] were)
        (VP (VBN:[1047..1055] detected)
          (NP-2 (-NONE-:[1055..1055] *)))))
    (,:[1055..1056] ,) (CC:[1057..1060] and)
    (S
      (NP-SBJ-3 (DT:[1061..1066] these) (NNS:[1068..1077] mutations))
      (VP (VBD:[1078..1082] were)
        (ADVP-TMP (RB:[1083..1093] frequently))
        (VP (VBN:[1094..1104] associated)
          (NP-3 (-NONE-:[1104..1104] *))
          (PP-CLR (IN:[1105..1109] with)
            (NP (JJ:[1110..1120] unbalanced) (JJ:[1121..1132] chromosomal)
                (NNS:[1133..1144] aberrations))))))
    (.:[1144..1145] .)))

;sentence 9 Span:1147..1241
;Furthermore, the spectrum of mutations was suggestive of an exposure to 
;alkylating chemicals.
;[1176..1185]:variation-event:"mutations"
(SENT
  (S
    (ADVP (RB:[1147..1158] Furthermore))
    (,:[1158..1159] ,)
    (NP-SBJ
      (NP (DT:[1160..1163] the) (NN:[1164..1172] spectrum))
      (PP (IN:[1173..1175] of)
        (NP (NNS:[1176..1185] mutations))))
    (VP (VBD:[1186..1189] was)
      (ADJP-PRD (JJ:[1190..1200] suggestive)
        (PP (IN:[1201..1203] of)
          (NP
            (NP (DT:[1204..1206] an) (NN:[1207..1215] exposure))
            (PP (TO:[1216..1218] to)
              (NP (VBG:[1220..1230] alkylating) (NNS:[1231..1240] chemicals)))))))
    (.:[1240..1241] .)))

;section 10 Span:1245..1289
;PMID: 9680114 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1245..1249] PMID) (::[1249..1250] :) (CD:[1251..1258] 9680114)
        (NN:[1259..1260] -LSB-) (NNP:[1260..1266] PubMed) (::[1267..1268] -)
        (NN:[1269..1276] indexed) (IN:[1277..1280] for)
        (NNP:[1281..1289] MEDLINE-RSB-)))
